Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007 - Wikidata - wikimedia - TriplyDB

Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007

Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007

http://www.wikidata.org/entity/Q33814896

about

Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009 Transmitted antiretroviral drug resistance in New York State, 2006-2008: results from a new surveillance system Patterns of transmitted HIV drug resistance in Europe vary by risk group Spatial epidemiology of recently acquired HIV infections across rural and urban areas of North Carolina Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis Primary drug resistance in South Africa: data from 10 years of surveys.Transmitted antiretroviral drug resistance in the men who have sex with men HIV patient cohort, Beijing, China, 2008-2011 Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.Differential persistence of transmitted HIV-1 drug resistance mutation classes.Low prevalence of the transmitted HIV-1 drug resistance among newly diagnosed HIV-1 individuals in Jiangsu Province, China during 2009-2011.Towards targeted screening for acute HIV infections in British Columbia HIV-1 Protease: Structural Perspectives on Drug Resistance Development and validation of the San Diego Early Test Score to predict acute and early HIV infection risk in men who have sex with men.Risk Factors for Acute and Early HIV Infection Among Men Who Have Sex With Men (MSM) in San Diego, 2008 to 2014: A Cohort Study.Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients.HIV treatment as prevention and HPTN 052.Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013.Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States.Phylogenetic insights into regional HIV transmission.Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis.Opportunities for sexual transmission of antiretroviral drug resistance among HIV-infected patients in care.Clinical management of acute HIV infection: best practice remains unknown.Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999-2014.A Simple Symptom Score for Acute HIV Infection in a San Diego Community Based Screening Program.

P2860

Q28476489-99D05FD3-CFF5-4244-A4D5-947316145696 Q28482098-6466C453-FF37-4BC3-B253-DC4D60E0FD06 Q28537726-84A47ABB-034B-4593-BFD0-81D5A6D9432F Q28539673-8308309C-FDE5-45B5-AD37-2A6CA8EE3FB8 Q28540964-BEB976BF-54D5-44F9-8940-5246079EC876 Q33988153-25DD6A3F-253D-4742-BDFA-BC6289CA0B80 Q34129300-04337DCD-149D-40BE-95A6-FB710C6FCFED Q34283967-A9C69ADA-E06D-4EB7-8543-6FE08A29106F Q34469240-048D9EDD-1375-41C3-9FB6-A96C8C291CB1 Q34529310-9B0789FF-B21F-4A1A-8A70-907E39C099C5 Q35022802-B2506F39-636F-4C00-8775-E0DD6D420D85 Q35090427-69FBAA3B-9E0E-4DA2-B18A-1669DC0CC5BB Q35203643-2FB79B7E-1FF3-45A9-8C56-46778AB71B18 Q35259855-5A1BF088-C692-4BFC-841F-49BE19EC4ED5 Q35975619-F0494E34-0052-440A-A26D-67D31373472E Q36009293-50AA3AA1-066E-49CE-B57F-FB63D96EE128 Q36274049-37D19C4E-882D-44FE-BA31-E28B6A320638 Q36279238-E9F1D05D-E58C-4BE9-AE57-A0336F86B7AC Q36364604-4E8D631E-EFCF-47F4-9B1D-07C4BDC9313D Q36460056-748104A8-1142-4311-A73D-A7590507F879 Q36509584-8CA4918B-40F1-4217-8D6F-0AEFF231985F Q36593951-243AA15E-BBB5-4567-AEDF-88C96DB53AE1 Q36601614-1FE18922-2CCF-414D-8CBA-B972369FF1EC Q37232818-ED34A0FE-9B0F-4F9B-BEB0-CDB61E525053 Q37565063-4E55F613-2804-43B7-B843-95DCB35E7D9B Q37789343-A8A1645D-7750-42B6-B422-7C198FD201E5 Q40047145-FD4CE7FF-EA4E-4E7E-9211-B19AB50BA1DC Q52401326-1D1909C5-318A-4CEF-90AF-57BB9DDA3185

P2860

Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007

http://www.wikidata.org/entity/Q33814896

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Transmitted antiretroviral dru ...... rth Carolina from 1998 to 2007

@ast

Transmitted antiretroviral dru ...... rth Carolina from 1998 to 2007

@en

type

label

Transmitted antiretroviral dru ...... rth Carolina from 1998 to 2007

@ast

Transmitted antiretroviral dru ...... rth Carolina from 1998 to 2007

@en

prefLabel

Transmitted antiretroviral dru ...... rth Carolina from 1998 to 2007

@ast

Transmitted antiretroviral dru ...... rth Carolina from 1998 to 2007

@en

P1433

Q33814896-83A2A9A5-75A3-43AB-A414-CB806176036F

P1476

Q33814896-9EEBBC4C-AE71-4AB8-A437-5427C69D78E2

P2093

Q33814896-122B1D38-0293-448B-8C63-A7E00DA955B5

Q33814896-1F69DEC6-4520-438A-B74A-6A45B3626319

Q33814896-36D75F9B-AC2C-4612-824D-7D503DB34017

Q33814896-392A7ED6-C3AB-4324-BA14-CD42EC353524

Q33814896-41F28005-6E63-4EEB-8F9D-EB39DF404FDE

Q33814896-55BF982E-0D62-427C-933E-A4517E008B27

Q33814896-75445BE4-BDFC-4C10-9306-1B28165E499F

Q33814896-8183CD55-9B02-4DAD-93DF-4CB44F5C8D6B

Q33814896-A38C0D31-B412-470E-AA21-F127460087D0

Q33814896-C92349A1-ADDD-42C4-9B60-3159E155AEEC

P2860

Q33814896-04A42478-E06D-465E-BE61-AF1C7B6F9B9C

Q33814896-0CAC69B2-650F-48D3-B9FE-E784D88E41F7

Q33814896-11BD8796-2A0D-430D-8959-3429735ECF8D

Q33814896-284742F4-6C4E-4C55-92A2-F06442C734F4

Q33814896-367637C8-1BB5-4DDF-9E9D-4252494291BA

Q33814896-52A3112D-74F7-49F3-BA11-7F42613C3BFE

Q33814896-631B4256-C000-499E-AB51-52B99C1A5FC0

Q33814896-6901FD56-67BC-47A6-A81B-396FEB9E6B99

Q33814896-70CE0BD2-24A9-44E4-9B67-CD3C8453AF02

Q33814896-77B28D17-3896-4A84-80AD-D772C8E1759D

P304

Q33814896-21E494D7-DB57-4B67-B334-027EE468DB1B

P31

Q33814896-1151B748-A2E8-4EAE-8CA8-1C8981FBAB29

P433

Q33814896-A9AB94E9-6F98-4FA3-9AB6-2D8AC69A21DD

P478

Q33814896-69CB77DB-18DD-49DD-8EB8-68CF237621B3

P50

Q33814896-E56B87E0-6B91-483F-941A-B6D4CF1D8CE5

P577

Q33814896-798BFCB3-A989-43B2-B343-F53C5ACB2A8B

P698

Q33814896-FD0A8DAE-BFCE-47B2-A844-8200E99142F3

P921

Q33814896-2E337DC4-B203-4E13-92C4-955E36CB80F5

Q33814896-4C2D5946-8EC8-470D-9AC0-548D586F0CEE

P932

Q33814896-266DA079-0DFF-4913-A2FA-8EFA90685DF4

P1433

Antiviral Therapy

P1476

Transmitted antiretroviral dru ...... rth Carolina from 1998 to 2007

@en

P2093

Charles Hicks

http://www.w3.org/2001/XMLSchema#string

Christopher B Hurt

http://www.w3.org/2001/XMLSchema#string

Christopher Pilcher

http://www.w3.org/2001/XMLSchema#string

Joann Kuruc

http://www.w3.org/2001/XMLSchema#string

Joseph Sebastian

http://www.w3.org/2001/XMLSchema#string

Julie Ae Nelson

http://www.w3.org/2001/XMLSchema#string

Kara McGee

http://www.w3.org/2001/XMLSchema#string

Melissa Kerkau

http://www.w3.org/2001/XMLSchema#string

Peter Leone

http://www.w3.org/2001/XMLSchema#string

Sandra I McCoy

http://www.w3.org/2001/XMLSchema#string

P2860

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons

Human immunodeficiency virus reverse transcriptase and protease sequence database

Time trends in primary HIV-1 drug resistance among recently infected persons.

Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom.

The risk environment for HIV transmission: results from the Atlanta and Flagstaff network studies.

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Update of the drug resistance mutations in HIV-1: 2007.

Class-sparing regimens for initial treatment of HIV-1 infection.

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.

P304

673-678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19704170

http://www.w3.org/2001/XMLSchema#string

P921

HIV transmission

antiretroviral drug

P932

2860724

http://www.w3.org/2001/XMLSchema#string